HC Wainwright Issues Pessimistic Outlook for LifeMD Earnings

Key Points

• HC Wainwright has revised down its Q1 2026 earnings estimate for LifeMD to $0.05 per share, decreasing from a previous estimate of $0.06, while maintaining a "Buy" rating and a price target of $13.00.
• Lake Street Capital has also cut its price target for LifeMD from $18.00 to $14.00 and downgraded the stock to a "buy" rating, while other analysts have varied in their ratings, resulting in a consensus rating of "Moderate Buy".
• LifeMD's stock is currently trading at $6.83, with a 52-week range of $3.99 to $15.84, indicating volatility and potentially offering a buying opportunity based on market sentiment.

LifeMD, Inc. (NASDAQ:LFMD - Free Report) - Stock analysts at HC Wainwright dropped their Q1 2026 earnings estimates for shares of LifeMD in a research note issued on Thursday, August 7th. HC Wainwright analyst Y. Chen now anticipates that the company will earn $0.05 per share for the quarter, down from their prior forecast of $0.06. HC Wainwright has a "Buy" rating and a $13.00 price target on the stock. The consensus estimate for LifeMD's current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for LifeMD's Q2 2026 earnings at $0.09 EPS, Q3 2026 earnings at $0.13 EPS, Q4 2026 earnings at $0.20 EPS and FY2026 earnings at $0.47 EPS.

Other equities analysts also recently issued reports about the stock. Lake Street Capital dropped their target price on shares of LifeMD from $18.00 to $14.00 and set a "buy" rating on the stock in a research note on Wednesday. Wall Street Zen downgraded shares of LifeMD from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. BTIG Research upped their target price on shares of LifeMD from $15.00 to $18.00 and gave the stock a "buy" rating in a research note on Wednesday, June 18th. Finally, KeyCorp dropped their target price on shares of LifeMD from $14.00 to $12.00 and set an "overweight" rating on the stock in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $12.86.

LifeMD Trading Up 3.3%

LifeMD stock traded up $0.22 during midday trading on Friday, reaching $6.83. The stock had a trading volume of 986,979 shares, compared to its average volume of 1,641,560. The company has a quick ratio of 0.77, a current ratio of 0.77 and a debt-to-equity ratio of 9.21. LifeMD has a 52-week low of $3.99 and a 52-week high of $15.84. The firm has a market cap of $310.42 million, a price-to-earnings ratio of -32.64 and a beta of 1.72. The company has a fifty day moving average of $11.97 and a 200 day moving average of $8.46.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.05. The firm had revenue of $65.70 million during the quarter, compared to analysts' expectations of $62.47 million.

Hedge Funds Weigh In On LifeMD

A number of hedge funds and other institutional investors have recently modified their holdings of LFMD. GAMMA Investing LLC purchased a new stake in LifeMD during the first quarter valued at approximately $35,000. CWM LLC raised its holdings in shares of LifeMD by 17.5% in the first quarter. CWM LLC now owns 9,050 shares of the company's stock worth $49,000 after buying an additional 1,351 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of LifeMD by 148.5% in the second quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company's stock worth $50,000 after buying an additional 2,185 shares during the last quarter. ProShare Advisors LLC purchased a new position in shares of LifeMD in the fourth quarter worth $51,000. Finally, Oxford Asset Management LLP purchased a new position in shares of LifeMD in the fourth quarter worth $52,000. 35.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling at LifeMD

In other news, CFO Marc David Benathen sold 75,000 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $13.09, for a total transaction of $981,750.00. Following the transaction, the chief financial officer directly owned 389,554 shares in the company, valued at approximately $5,099,261.86. This trade represents a 16.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Justin Schreiber sold 25,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $13.38, for a total transaction of $334,500.00. Following the transaction, the chief executive officer owned 2,500,721 shares in the company, valued at approximately $33,459,646.98. This represents a 0.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 275,000 shares of company stock valued at $3,564,550 in the last ninety days. Company insiders own 18.40% of the company's stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.